SCHEMBL1663509

SCHEMBL1663509

CC(C)c1nc2cc(O)ccc2c(=O)n1CC(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.48
HDAC1 Q13547 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA13 Q8N1Q1 1/20 0.45
RXFP1 Q9HBX9 1/20 0.43
LMNA P02545 2/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
AKR1B1 P15121 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CXCR3 P49682 1/20 0.41
GFER P55789 1/20 0.39
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
GPR35 Q9HC97 1/20 0.39
PDE5A O76074 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1664148 0.78 TRPV1 (0.54) TRPV1HDAC1HDAC6LMNAALDH1A1
SCHEMBL1663421 0.78 TRPV1 (0.54) TRPV1HDAC1HDAC6ALDH1A1AKR1B1
SCHEMBL1663885 0.76 ALOX5AP (0.52) TRPV1HDAC1HDAC6LMNAALDH1A1
SCHEMBL1663099 0.76 TRPV1 (0.47) TRPV1HDAC1HDAC6LMNAALDH1A1
SCHEMBL1663306 0.75 TRPV1 (0.51) TRPV1HDAC1HDAC6ALDH1A1AKR1B1
SCHEMBL1663609 0.75 TRPV1 (0.51) TRPV1HDAC1HDAC6RXFP1ALDH1A1
SCHEMBL1663283 0.74 TRPV1 (0.50) TRPV1HDAC1HDAC6MAPTAKR1B1
SCHEMBL1663914 0.74 TRPV1 (0.50) TRPV1HDAC1HDAC6ALDH1A1AKR1B1
SCHEMBL1663625 0.74 TRPV1 (0.50) TRPV1HDAC1HDAC6ALDH1A1KDM4E
SCHEMBL1663843 0.74 AKR1B1 (0.48) TRPV1LMNAALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
CN-101356160-A Trisubstituted quinazolinone derivatives as vanilloid antagonists JANSSEN PHARMACEUTICA NV (CH) 2009-01-28 CN disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885HDAC1 999/4885HDAC6 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.